Therefore, ERBB2/3 and EGFR are ideal tumor-associated antigens, which are suitable for binding with T and B cell activators such as CD3 and CD40 agonists to construct bispecifics, and kill tumor cells by bridging immune cells to tumor. Here, CD40 is linked to neoplasm.